Immunotherapy duo takes on resistant germ cell tumors

NCT ID NCT03158064

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed after prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and tremelimumab (immunotherapy drugs)
What this could lead to: If successful, this could offer a new treatment option for patients with germ cell tumors that have not responded to standard therapy.
What could go wrong: This is a small, early-phase trial with only 30 participants. The drugs may not shrink tumors effectively, and immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSGERMINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dysgerminoma germ cell tumor germinoma germinomatous germ cell tumor malignant pineal area germ cell neoplasm Neoplasms, Germ Cell and Embryonal nongerminomatous germ cell tumor Nonseminomatous germ cell tumor pineal region germinoma seminoma testis refractory cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSGERMINOMA GERM CELL TUMOR GERMINOMATOUS GERM CELL TUMOR NONSEMINOMATOUS GERM CELL TUMOR PINEAL GERM CELL TUMOR SEMINOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.